Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2020 Jul 9

PMID 32640027

Citations 2

Authors

X Anton Alvarez

Irene Alvarez

Antia Martinez

Iria Romero

Concha Benito

Irene Suarez

Silvia Mourente

Manuel Fantini

Jesus Figueroa

Manuel Aleixandre

Carlos Linares

Dafin Muresanu

Stefan Winter

Herbert Moessler

Affiliations

Soon will be listed here.

Abstract

Serum vascular endothelial growth factor (VEGF) increases with Alzheimer's disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is limited. This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial. Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels. Our results indicate that the combined therapy reversed the increase of serum VEGF in advanced AD, which was associated with cognitive and functional responses, particularly in patients with high baseline VEGF.

Citing Articles

Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil.

Alvarez X, Winston C, Barlow J, Sarsoza F, Alvarez I, Aleixandre M J Alzheimers Dis. 2022; 90(2):705-717.

PMID: 36155516 PMC: 9697063. DOI: 10.3233/JAD-220575.

Decreased Netrin-1 in Mild Cognitive Impairment and Alzheimer's Disease Patients.

Ju T, Sun L, Fan Y, Wang T, Liu Y, Liu D Front Aging Neurosci. 2022; 13:762649.

PMID: 35250531 PMC: 8888826. DOI: 10.3389/fnagi.2021.762649.

References

Eder P, Korybalska K, Lykowska-Szuber L, Krela-Kazmierczak I, Stawczyk-Eder K, Klimczak K . Association of serum VEGF with clinical response to anti-TNFα therapy for Crohn's disease. Cytokine. 2015; 76(2):288-293. DOI: 10.1016/j.cyto.2015.09.018. View

Leyhe T, Hoffmann N, Stransky E, Laske C . Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int J Neuropsychopharmacol. 2009; 12(10):1319-26. DOI: 10.1017/S1461145709990216. View

Alvarez X, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M . Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res. 2011; 8(5):583-91. DOI: 10.2174/156720511796391863. View

Wood L, Winslow A, Proctor E, McGuone D, Mordes D, Frosch M . Identification of neurotoxic cytokines by profiling Alzheimer's disease tissues and neuron culture viability screening. Sci Rep. 2015; 5:16622. PMC: 4643219. DOI: 10.1038/srep16622. View

Alvarez X, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E . Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. 2010; 18(1):59-68. DOI: 10.1111/j.1468-1331.2010.03092.x. View

Ryu J, Cho T, Choi H, Wang Y, McLarnon J . Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology. J Neurosci. 2009; 29(1):3-13. PMC: 6664925. DOI: 10.1523/JNEUROSCI.2888-08.2009. View

Haneda Y, Hasegawa S, Hirano R, Hashimoto K, Ohsaki A, Ichiyama T . Leukotriene D4 enhances tumor necrosis factor-α-induced vascular endothelial growth factor production in human monocytes/macrophages. Cytokine. 2011; 55(1):24-8. DOI: 10.1016/j.cyto.2011.03.018. View

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose J . Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 2006; 83(7):1252-61. DOI: 10.1002/jnr.20818. View

Gauthier S, Proano J, Jia J, Froelich L, Vester J, Doppler E . Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015; 39(5-6):332-47. DOI: 10.1159/000377672. View

10.

Alvarez X, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M . Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. Int J Neuropsychopharmacol. 2016; 19(6). PMC: 4926802. DOI: 10.1093/ijnp/pyw024. View

11.

Cho S, Park M, Han C, Yoon K, Koh Y . VEGFR2 alteration in Alzheimer's disease. Sci Rep. 2017; 7(1):17713. PMC: 5735090. DOI: 10.1038/s41598-017-18042-1. View

12.

Religa P, Cao R, Religa D, Xue Y, Bogdanovic N, Westaway D . VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep. 2013; 3:2053. PMC: 3690383. DOI: 10.1038/srep02053. View

13.

Alvarez X, Sampedro C, Cacabelos R, Linares C, Aleixandre M, Garcia-Fantini M . Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. Int J Neuropsychopharmacol. 2009; 12(7):867-72. DOI: 10.1017/S1461145709990101. View

14.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A . Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. Stem Cell Res. 2015; 15(1):54-67. DOI: 10.1016/j.scr.2015.04.008. View

15.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P . Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin. 2002; 18(6):347-54. DOI: 10.1185/030079902125001029. View

16.

Garcia K, Ornellas F, Martin P, Patti C, Mello L, Frussa-Filho R . Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer's disease. Front Aging Neurosci. 2014; 6:30. PMC: 3945612. DOI: 10.3389/fnagi.2014.00030. View

17.

Jais A, Solas M, Backes H, Chaurasia B, Kleinridders A, Theurich S . Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity. Cell. 2016; 165(4):882-95. DOI: 10.1016/j.cell.2016.03.033. View

18.

Wang P, Xie Z, Guo Y, Zhao C, Jiang H, Song Y . VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. Biochem Biophys Res Commun. 2011; 411(3):620-6. DOI: 10.1016/j.bbrc.2011.07.003. View

19.

Sanchez A, Tripathy D, Luo J, Yin X, Martinez J, Grammas P . Neurovascular unit and the effects of dosage in VEGF toxicity: role for oxidative stress and thrombin. J Alzheimers Dis. 2012; 34(1):281-91. DOI: 10.3233/JAD-121636. View

20.

Gschanes A, Boado R, Sametz W, Windisch M . The drug cerebrolysin and its peptide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats. Histochem J. 2000; 32(2):71-7. DOI: 10.1023/a:1004003008683. View